Adropin protects against cardiac remodeling and metabolic dysfunction in a mouse model of HFpEF
Bellina A.S. Mushala, Michael Wayne Stoner, Maryam Sharifi‐Sanjani, Janet R. Manning, Paramesha Bugga, Nisha Bhattarai, Brenda McMahon, Amber M. Vandevender, Steven J. Mullett, Brett A. Kaufman, Sruti S. Shiva, Cheng Zhang, Eric S. Goetzman, Stephen Y. Chan, Stacy L. Gelhaus, , Iain Scott
This study shows Adropin treatment reverses cardiac dysfunction and metabolic defects in a mouse model of HFpEF by reducing O-GlcNAcylation of LCAD and improving fatty acid oxidation.
bioRxiv · May 3, 2025 · PreprintPhysiology